|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.440 USD | -0.91% |
|
-2.33% | +59.53% |
| Jun. 16 | CureVac agrees to pay Biontech termination fee Of $43.8 mln under specified circumstances | RE |
| Jun. 13 | Jefferies Downgrades CureVac to Hold From Buy, $5 Price Target | MT |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
Biological Products | |||||||
Discovery and Development of Biotechnological Applications | 48.87M | 103M | 67.42M | 53.76M | 535M | ||
Total Assets | 1.51B | 1.16B | 860M | 788M | 803M | ||
Interest Expense | -22.1M | -10.34M | -3.71M | - | - | ||
Income Tax Expense | -726K | -782K | -126K | 198K | 28.7M | ||
CAPEX | -47.35M | -128M | -93.22M | -52.32M | -14.32M | ||
EBT | -130M | -412M | -249M | -260M | 191M | ||
D&A | 9.54M | 13.51M | 21.8M | 22.57M | 17.91M | ||
Operating Income | -110M | -412M | -249M | -274M | 178M | ||
Net Income | -129M | -412M | -249M | -260M | 162M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
Belgium | 8.81M | 74.3M | 62.26M | 47.13M | 520M | ||
Switzerland | 695K | 919K | 3.37M | 5.42M | 12.95M | ||
Netherlands | 2.63M | 1.77M | 1.79M | 1.2M | 2.38M | ||
Others | - | - | - | 8K | - | ||
Germany | 1.88M | 26M | - | - | - | ||
United States | 34.85M | - | - | - | - |
- Stock Market
- Equities
- CVAC Stock
- Financials CureVac N.V.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
